Newsbenzinga
FDA Declines To Approve Achieve Life Sciences' Smoking Cessation Drug; Q4 Resubmission Planned
· Published
Article summary
FDA rejects Achieve Life Sciences application for cytisinicline tied to manufacturing issues, with NDA resubmission planned in Q4 2026.
An excerpt from the original article.
Comments —
Loading comments…